Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Boulware and colleagues1 concluded that a strategy of annual dipstick screening
for proteinuria with follow-up testing and treatment with an angiotensin-converting
enzyme (ACE) inhibitor would not be cost-effective to slow progression of
kidney disease or to decrease mortality. We believe that their results were
strongly influenced by a number of factors, including the low yield of the
screening test, the high costs for the screening by the primary care physician,
and the possible added reduction of cardiovascular morbidity that is not taken
Gansevoort RT, de Jong PE, Postma MJ. Cost-effectiveness of Screening for Proteinuria. JAMA. 2004;291(12):1442–1443. doi:10.1001/jama.291.12.1442
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: